Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Harvard Business School
Dow
Daiichi Sankyo
Chinese Patent Office
Medtronic
Citi
Cerilliant

Generated: July 20, 2018

DrugPatentWatch Database Preview

PARICALCITOL - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for paricalcitol and what is the scope of paricalcitol patent protection?

Paricalcitol
is the generic ingredient in two branded drugs marketed by Amneal Pharms, Aurobindo Pharma Ltd, Bionpharma Inc, Dr Reddys Labs Ltd, Lotus Pharm Co Ltd, Marksans Pharma, Rising Pharms Inc, Teva Pharms Usa, Abbvie, Accord Hlthcare, Akorn, Amneal Pharms Co, Hikma Pharms, Hospira Inc, Mylan Labs Ltd, and Sandoz Inc, and is included in eighteen NDAs. There are two patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Paricalcitol has seventeen patent family members in ten countries.

There are ten drug master file entries for paricalcitol. Twenty suppliers are listed for this compound. There is one tentative approval for this compound.
Pharmacology for PARICALCITOL
Ingredient-typeCholecalciferol
Drug ClassVitamin D3 Analog
Synonyms for PARICALCITOL
(1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol
(1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol
(1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol
(1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,1R,4S)-5-hydroxy-1,4,5-trimethyl-hex-2-enyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
(7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol
131918-61-1
19-Nor-1-alpha,25-dihydroxyvitamin D2
19-Nor-1,25-(OH)2D2
19-Nor-1,25-dihydroxyvitamin D2
19-Nor-1alpha,25-dihydroxyvitamin D2
19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-
19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol,(1alpha,3beta,7E,22E)
6702D36OG5
918P611
Ab 122358
Abbott brand of paricalcitol
ABT-358
AC1NQY0Z
ACT07192
AKOS005145562
AN-15155
BC680819
BCP9001050
BDBM233195
BIDD:GT0330
BPKAHTKRCLCHEA-UBFJEZKGSA-N
C08127
CAS-131918-61-1
CHEBI:7931
CHEMBL1200622
Compound 49510
Compound-49510
CS-0705
D00930
D0N1TP
DB00910
DSSTox_CID_28566
DSSTox_GSID_48640
DSSTox_RID_82838
DTXSID4048640
GTPL2791
HSDB 7360
HY-50919
LMST04030163
LS-172812
MolPort-006-167-660
NCGC00182706-01
OR009715
OR213437
Paracalcin
Paricalcitol (JAN/USAN/INN)
Paricalcitol (USAN/INN)
Paricalcitol [USAN:USP:INN]
Paricalcitol [USAN]
Paricalcitol, 19-nor-(OH)2-vitD2, paracalcin
PubChem18825
SC-20905
SCHEMBL3655
Tox21_112987
UNII-6702D36OG5
W-5365
Zemplar
Zemplar (TN)
ZINC13911941
Tentative approvals for PARICALCITOL
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial2MCG/MLINJECTABLE; INJECTION
➤ Try a Free Trial➤ Try a Free Trial10MCG/MLINJECTABLE; INJECTION
➤ Try a Free Trial➤ Try a Free Trial5MCG/MLINJECTABLE; INJECTION

US Patents and Regulatory Information for PARICALCITOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd PARICALCITOL paricalcitol CAPSULE;ORAL 207672-001 Jan 14, 2016 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira Inc PARICALCITOL paricalcitol SOLUTION;INTRAVENOUS 201657-002 Oct 21, 2014 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-002 Feb 1, 2000 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for PARICALCITOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-002 May 26, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-001 Apr 17, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol CAPSULE;ORAL 021606-003 May 26, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Abbvie ZEMPLAR paricalcitol SOLUTION;INTRAVENOUS 020819-002 Feb 1, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for PARICALCITOL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB04/003 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PARICALCITOL; REGISTERED: ES SPAIN 64.974 20020809; UK PL 00037/0403 20030721
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Cerilliant
Farmers Insurance
Mallinckrodt
McKinsey
US Department of Justice
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.